2. Signaling Pathways
  3. MAPK/ERK Pathway
  4. JNK
  5. JNK Agonist

JNK Agonist

JNK Isoform Comparison

JNK Agonists (5):

Cat. No. Product Name Effect Purity
  • HY-173188
    EGFR-IN-154
    		Agonist
    EGFR-IN-154 (compound 4c) is an EGFR inhibitor with EC50 values of 0.16 μM, 21.73 μM and 41.56 μM against EGFR Del19, EGFR WT and EGFR L858R, respectively. EGFR-IN-154 shows anticancer activity on various cance cell lines. EGFR-IN-154 induces mitochondrial apoptosis, and decreases pERK1/2 and pAkt levels, but increases pJNK and pp38 levels.
  • HY-N1508
    Ecliptasaponin A
    		Agonist 99.50%
    Ecliptasaponin A is an orally active pentacyclic triterpenoid saponin. Ecliptasaponin A exerts anti-tumor activity by activating ASK1/JNK pathway, inducing apoptosis and autophagy in lung cancer cells. Ecliptasaponin A exerts anti-inflammatory/anti-fibrotic effects and protects the cardiovascular system by inhibiting the HMGB1/TLR4/NF-κB pathway, and the expression of COX-2 and MMP-9. Ecliptasaponin A can enhance SOD activity, reduce MDA levels, and alleviate oxidative stress damage. Ecliptasaponin A exerts chondroprotective effects by inhibiting the expression of MMP13 and regulating inflammatory factors. Ecliptasaponin A improves ovarian function and regulates sex hormones by upregulating the expression of ESR1 receptors.
  • HY-128671
    6-​Thioinosine
    		Agonist 99.31%
    6-Thioinosine (6TI) is a purine antimetabolite and an anti-adipogenic agent. 6-Thioinosine reduces the mRNA levels of PPARγ and C/EBPα and downregulates the mRNA levels of PPARγ target genes (LPL, CD36, aP2, and LXRα). 6-Thioinosine exerts its anti-adipogenic effects by downregulating PPARγ through JNK-dependent iNOS upregulation. 6-Thioinosine can be used to study adipocyte dysfunction.
  • HY-103074
    GSK2226649A
    		Agonist
    GSK2226649A (compound 2) is a novel activator of satellite cell proliferation and enhanced repair of damaged muscle.
  • HY-N1508R
    Ecliptasaponin A (Standard)
    		Agonist
    Ecliptasaponin A (Standard) is the analytical standard for Ecliptasaponin A (HY-N1508). Ecliptasaponin A is an orally active pentacyclic triterpenoid saponin. Ecliptasaponin A exerts anti-tumor activity by activating ASK1/JNK pathway, inducing apoptosis and autophagy in lung cancer cells. Ecliptasaponin A exerts anti-inflammatory/anti-fibrotic effects and protects the cardiovascular system by inhibiting the HMGB1/TLR4/NF-κB pathway, and the expression of COX-2 and MMP-9. Ecliptasaponin A can enhance SOD activity, reduce MDA levels, and alleviate oxidative stress damage. Ecliptasaponin A exerts chondroprotective effects by inhibiting the expression of MMP13 and regulating inflammatory factors. Ecliptasaponin A improves ovarian function and regulates sex hormones by upregulating the expression of ESR1 receptors.